Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright
HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $20.00 target price on the stock. Separately, Wedbush restated an outperform rating and issued a $11.00 price target on shares of Aprea Therapeutics in a […]
More Stories
Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Down 19.8% in September
Lantern Pharma Inc. (NASDAQ:LTRN – Get Free Report) saw a large decrease in short interest in September. As of September...
Mobico Group Plc (OTCMKTS:NXPGF) Sees Significant Decline in Short Interest
Mobico Group Plc (OTCMKTS:NXPGF – Get Free Report) saw a large drop in short interest in the month of September....
Maple Leaf Foods Inc. (OTCMKTS:MLFNF) Short Interest Update
Maple Leaf Foods Inc. (OTCMKTS:MLFNF – Get Free Report) saw a large drop in short interest in the month of...
Lotus Resources Limited (OTCMKTS:LTSRF) Sees Large Decline in Short Interest
Lotus Resources Limited (OTCMKTS:LTSRF – Get Free Report) was the recipient of a large decline in short interest in September....
BOC Aviation Limited (OTCMKTS:BCVVF) Short Interest Down 25.6% in September
BOC Aviation Limited (OTCMKTS:BCVVF – Get Free Report) was the target of a large drop in short interest during the...
Nature’s Skin-Saving Super Ingredient Is Found in Plants
By Zena le Roux Hippocrates was onto something when he said, “Let food be thy medicine and medicine be thy...